8-K: Amgen Reports Strong Q3 2026 Results, Revenue Up 8%

Amgen announced robust third quarter 2026 financial results, with total revenues climbing 8% year-over-year to $10.4 billion, driven by strong product sales and pipeline progress.

Summary

• Amgen reported strong financial results for the third quarter of 2026, with total revenues increasing by 8% to $10.4 billion compared to the third quarter of 2025.
• Product sales also grew by 8%, fueled by volume increases, with seventeen products achieving at least double-digit sales growth and seventeen products annualizing over $1 billion.
• GAAP earnings per share (EPS) saw a significant increase of 19%, rising to $7.08 from $5.93 in the prior year's quarter.
• GAAP operating income grew from $2.5 billion to $3.7 billion, with the operating margin expanding by 9.9 percentage points to 37.5%.
• Non-GAAP EPS increased by 14% to $6.45, and non-GAAP operating income rose to $4.7 billion, with a slight increase in operating margin to 47.3%.
• Free Cash Flow (FCF) for the quarter was $3.7 billion, a decrease from $4.2 billion in Q3 2025, attributed to working capital changes.
• The company provided full-year 2026 guidance, expecting total revenues between $38.9 billion and $39.7 billion, and GAAP EPS between $18.34 and $19.28.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and significant increases in GAAP EPS, driven by robust product sales and pipeline advancements.

Positives

• Total revenues increased by 8% year-over-year to $10.4 billion in Q3 2026.
• Product sales grew by 8%, driven by volume growth.
• Seventeen products achieved at least double-digit sales growth in the quarter.
• Seventeen products are annualizing at over $1 billion based on Q3 sales.
• GAAP EPS increased by 19% to $7.08.
• GAAP operating income increased to $3.7 billion, with operating margin improving to 37.5%.
• Non-GAAP EPS increased by 14% to $6.45.
• Repatha sales increased 37% to $1,085 million, EVENITY sales increased 39% to $751 million, and UPLIZNA sales increased 191% to $451 million.
• IMDELLTRA sales increased 128% to $406 million, and BLINCYTO sales increased 27% to $496 million.
• TEZSPIRE sales increased 43% to $538 million.
• The company is advancing a broad and deep pipeline with numerous Phase 3 studies across various therapeutic areas.

Negatives

• Prolia sales decreased 45% year-over-year to $632 million due to biosimilar launches.
• TEPEZZA sales decreased 6% year-over-year to $526 million, driven by lower inventory levels.
• TAVNEOS sales decreased 2% year-over-year to $105 million.
• Otezla sales decreased 18% year-over-year to $481 million, driven by lower volume and unfavorable changes to sales deductions.
• KYPROLIS sales decreased 8% year-over-year to $330 million, primarily driven by lower volume.
• XGEVA sales decreased 47% year-over-year to $288 million due to biosimilar launches.
• MVASI sales decreased 21% year-over-year to $168 million.
• Free Cash Flow decreased to $3.7 billion from $4.2 billion in Q3 2025, due to changes in working capital.

Risks

• The company faces ongoing competition from biosimilars, impacting sales of products like Prolia and XGEVA.
• Regulatory engagement with the FDA regarding the potential voluntary withdrawal of TAVNEOS from the U.S. market continues.
• Certain clinical studies, such as the Phase 2 study of subcutaneous blinatumomab, remain on partial clinical hold by the FDA.
• The company's forward-looking statements are subject to significant risks and uncertainties, including clinical and regulatory developments, competition, manufacturing difficulties, and global economic conditions.

Future Outlook

For the full year 2026, Amgen expects total revenues in the range of $38.9 billion to $39.7 billion. GAAP EPS is projected to be between $18.34 and $19.28, with a GAAP tax rate of 14.5% to 16.0%. Non-GAAP EPS is guided between $22.90 and $23.70, with a non-GAAP tax rate of 15.0% to 16.5%. Capital expenditures are expected to be approximately $2.6 billion, and share repurchases are not expected to exceed $3.0 billion.

Management Comments

• "Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise," said Robert A. Bradway, chairman and chief executive officer.
• "The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade."

Industry Context

StockSavvy.ai notes that Amgen's performance in Q3 2026 reflects continued strength in the biopharmaceutical sector, particularly in areas like cardiovascular health and rare diseases. The company's focus on a robust pipeline, including significant investment in weight management (MariTide) and oncology, positions it to address major health challenges and capitalize on evolving market demands. The impact of biosimilars on certain established products highlights the dynamic competitive landscape.

Comparison to Industry Standards

• Amgen's revenue growth of 8% in Q3 2026 is strong compared to the broader pharmaceutical industry average, which has seen more moderate growth in recent periods.
• The significant increase in GAAP EPS (19%) and operating margin (9.9 percentage points) suggests efficient operations and successful product performance, outperforming many peers who may be facing pricing pressures or higher R&D costs.
• The company's investment in R&D, increasing by 11% year-over-year on both GAAP and non-GAAP bases, aligns with industry trends of prioritizing innovation to drive future growth, especially in complex therapeutic areas like oncology and rare diseases.
• The performance of key growth drivers like Repatha (37% sales increase) and EVENITY (39% sales increase) demonstrates Amgen's ability to successfully commercialize innovative therapies, a critical factor for success in the biopharmaceutical industry.

Legal Proceedings

• The Company continues to engage with the U.S. Food and Drug Administration (FDA) regarding the Center for Drug Evaluation and Research's request to voluntarily withdraw TAVNEOS from the U.S. market. The Company requested a hearing on June 1, 2026, and submitted supporting materials on July 23, 2026.

Stakeholder Impact

• Shareholders: The strong financial results and positive outlook are likely to be viewed favorably by shareholders, potentially supporting stock price appreciation.
• Employees: Continued investment in R&D and pipeline development suggests ongoing opportunities and job security within the company.
• Patients: Advancements in the pipeline and continued sales of key therapies offer potential benefits for patients seeking treatments for serious diseases.
• Creditors: The company's solid financial position, with significant cash reserves and manageable debt levels, provides confidence to creditors.

Next Steps

• Continue advancing the MariTide Phase 3 studies for chronic weight management, cardiovascular outcomes, heart failure events, and obstructive sleep apnea.
• Initiate two additional Phase 3 studies of MariTide in patients with Type 2 diabetes in Q4 2026.
• Advance the OCEAN(a)-Outcomes and OCEAN(a)-PreEvent Phase 3 studies for olpasiran.
• Initiate Phase 3 studies for UPLIZNA in autoimmune hepatitis (AIH) and primary membranous nephropathy (PMN).
• Initiate a Phase 3 study for UPLIZNA in chronic inflammatory demyelinating polyneuropathy (CIDP) in H2 2026 H1 2027.
• Advance daxdilimab to Phase 3 development.
• Submit Otezla safety findings in pediatric patients to the FDA.
• Continue advancing the comprehensive clinical development program for IMDELLTRA across extensive-stage and limited-stage SCLC.

Key Dates

Recommendation

Amgen delivered strong Q3 results with significant revenue and EPS growth, driven by its commercial portfolio and pipeline advancements. However, the impact of biosimilars on key products like Prolia and XGEVA, coupled with ongoing regulatory scrutiny for TAVNEOS, introduces some uncertainty. While the pipeline is robust, the long development cycles and competitive landscape warrant a cautious 'hold' rating, pending further clarity on regulatory outcomes and sustained growth from new product launches.

Keywords

Amgen, Third Quarter, Financial Results, Revenue, EPS, Biotechnology, Pharmaceuticals, Pipeline